Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

“The approval of Sumitomo Pharma's Amchepry makes it the world's first commercialized medical product derived from iPS cells.

Summary generated from the RSS feed of Japan Times Latest. All article rights belong to the original publisher. Click through to read the full piece on www.japantimes.co.jp.